Foresite Capital Portfolio
13F Holdings & Position Changes — Last filed Aug 14, 2026
13F Holdings & Position Changes — Last filed Aug 14, 2026
Foresite Capital is a $4B biotech-focused hedge fund managed by Jim Tananbaum, MD. As of their latest 13F filing (Q2 2026), the fund holds 6 positions worth $290.2M. This quarter they initiated 1 new position and exited 10. Their largest holding is PHVS ($165.2M).
Foresite initiated 1 new position and increased 2 this quarter. Portfolio grew +22.4% to $290.2M. 40 upcoming catalysts across holdings.
Track this fund’s next move
13F changes, conviction shifts, and catalyst alerts across all 20 specialist biotech funds — free Monday brief.
Foresite Capital held 6 biotech stocks in their 13F portfolio this quarter. Their top positions include PHVS, CYTK, EIKN, RLAY, XENE. The full holdings table is available on BiotechEdge with position sizes, quarter-over-quarter changes, and AI analysis.
Foresite Capital's tracked biotech portfolio is worth $290.2M across 6 positions, with total assets under management of approximately $4B. Portfolio values are based on 13F filings with the SEC.
Foresite Capital initiated 1 new position this quarter, including CRNX. They also increased 2 existing positions.
Foresite Capital fully exited 10 positions this quarter, including ALEC, LYEL, QSIAW, MAZE, ACRS and 5 more. They also trimmed 0 existing positions.
Data science-driven healthcare crossover fund investing from late-stage private through public equity. Uses proprietary data analytics and clinical expertise to identify asymmetric risk/reward opportunities across biotech and life sciences.